Participants in this study will receive injections of the study drug into their skin lesions. During the course of the trial, the response to the treatment will be observed through visual changes and pathological examination, which involves looking at tissue samples under a microscope to check for cancer cells. The study also monitors for any side effects or health issues that may occur during or after the treatment process.

The purpose of this study is to find out how well these treatments work for people with this type of skin cancer who cannot have surgery or radiation therapy, or who have chosen not to have these treatments. The study will compare the different treatment options to see which one is most effective. People taking part in this study will have a skin cancer that has either come back after previous surgeries or is in a location where surgery would cause significant problems or changes to appearance.

During the study, participants will receive injections of one of the study medications directly into their skin tumor over a period of several weeks. The study team will monitor how the tumor responds to treatment and will check for any side effects. The treatments are given in cycles, and participants will be followed to see how well the medication works at controlling or shrinking the cancer. The study is designed to help doctors understand whether these new treatment options could be helpful for people with this type of skin cancer who need alternatives to surgery or radiation.

The purpose of this study is to see how well these two medications work when injected directly into the tumor in patients whose cancer has continued to grow or who could not tolerate previous treatments. The medications work by helping the body’s immune system fight the cancer cells. During the study, patients will receive the treatment injections over a period of several weeks, and doctors will monitor how the tumors respond to the treatment.

Patients participating in this study will need to have at least one tumor that can be injected and measured. Before starting treatment and during the study, small tissue samples will be taken from the tumor to check how it is responding. The study will track changes in the size and appearance of the tumors to determine whether the treatment is helping. Regular check-ups and tests will be done to monitor both the effectiveness of the treatment and any side effects that may occur.

The purpose of this study is to evaluate both the safety and effectiveness of this combination therapy in patients with high-risk basal cell carcinoma that could potentially be removed by surgery. The study is conducted in two parts: Phase Ib focuses on safety and side effects, while Phase II examines how well the treatment works at preventing cancer from returning after surgery.

Participants in this study will receive the combination treatment before undergoing surgical removal of their tumor. Throughout the study, doctors will monitor patients for side effects and assess how the tumor responds to treatment. They will also track whether the cancer returns over a three-year period following treatment.

The purpose of the study is to compare the effects of electrochemotherapy with those of standard radiotherapy in treating basal cell carcinomas that are less than 3 cm in size. Participants in the study will receive either electrochemotherapy or radiotherapy, and the effects of these treatments will be observed and compared. The study will also monitor any side effects, the cosmetic outcomes of the treatments, and the satisfaction of the participants with the treatment they receive.

The study will take place over several years, with participants being monitored throughout the treatment process. The goal is to determine which treatment is more effective and to gather information on the overall experience of the participants. This information will help in understanding the best approach to treating basal cell carcinoma in the future.

The purpose of this study is to determine how well cemiplimab works and how safe it is when used as the initial treatment for advanced basal cell carcinoma that cannot be treated with surgery or radiation therapy. During the study, participants will receive cemiplimab infusions at a dose of 350 mg every three weeks for up to 51 weeks.

Throughout the treatment period, doctors will monitor participants’ response to the medication and check for any side effects. The study will track various aspects of the treatment’s effectiveness, including how many patients show improvement, how long the treatment works, and how long patients survive after starting the treatment. Blood samples and tissue samples will be collected to help understand how the medication affects the cancer.

Participants in the study will undergo either electrochemotherapy or photodynamic therapy. Throughout the study, the changes in the blood vessels will be monitored at different depths of the skin before and after the treatment. This will help researchers understand how the treatments work on a microscopic level. Additionally, the study will look at factors like the thickness and density of the cancer, as well as any side effects such as skin darkening, to see how they might influence the treatment outcomes. The quality of life of participants will also be assessed to understand the impact of these treatments on their daily lives.

The study aims to provide valuable insights into the effectiveness of these non-surgical treatments for basal cell carcinoma and to identify any predictors of successful treatment outcomes. By understanding the changes in blood vessels and other factors, researchers hope to improve treatment strategies for this common skin cancer.

The purpose of the study is to evaluate how well these treatments work in shrinking or eliminating the tumors. Participants in the study will receive either the active treatment or a placebo. The study will last for a period of up to four months, during which the medications will be administered directly into the tumor. The effectiveness of the treatment will be assessed by looking at the overall response of the tumors, which includes both complete disappearance and partial reduction in size.

Throughout the study, the safety of the treatments will also be monitored. This means that any side effects or reactions to the medications will be carefully observed and recorded. The goal is to determine not only how effective the treatments are but also how safe they are for patients with these types of skin cancer. Participants will be required to attend regular visits for treatment and monitoring during the study period.

Participants in the study will apply the Tirbanibulin ointment to the affected area of their skin. The study will monitor the treatment’s effectiveness by checking for complete remission, which means there is no evidence of the cancer remaining. The study will also keep track of any side effects that may occur, noting their type, frequency, and severity. These side effects will be assessed using a standard scale to ensure they are properly understood and managed.

The study will take place over a period of time, with participants being observed for changes in their condition after one or more cycles of treatment. The thickness of the basal cell carcinoma will be measured using a special imaging technique to help determine the treatment’s success. The overall goal is to see if Tirbanibulin can effectively treat this type of skin cancer while maintaining a good safety profile for patients.

Participants in the study will take sonidegib according to a tailored schedule. This means they will have specific periods when they take the medication and periods when they do not. The study will last for up to two years, and during this time, researchers will monitor how well patients stick to the treatment plan and how their condition responds. The study will also look at the safety of the treatment and any side effects that may occur.

Throughout the study, patients will have regular check-ups to assess their health and the effectiveness of the treatment. This will include taking images of the affected skin areas to see how they change over time. The study aims to provide valuable information on how to best manage treatment for patients with locally advanced basal cell carcinoma using sonidegib.

Participants in the study will receive Balstilimab and will be monitored over a period of time to assess the safety and effectiveness of the treatment. The study will look at how well the cancer responds to the treatment, whether it remains stable, shrinks, or disappears. The study will also track how long any positive effects last and monitor any side effects that may occur. Patients will have regular check-ups and tests to see how the treatment is affecting their health and the cancer.

The study aims to gather information on the overall survival rates of patients at 12 and 24 months after starting the treatment. It will also collect data on any changes in patients’ quality of life and general health. This information will help researchers understand if Balstilimab can be a beneficial treatment option for people with advanced non-melanoma skin cancers.